Healthcare / Diagnostics / Signal Release

Press Release

Companion Diagnostics Compounds at 9.72 Per Cent and Pharmacogenomics at 5.90 in the Same Laboratories — a Drug Label Is Binding and a Clinical Guideline Is Not

· Healthcare

Pheonix Research has published Global Companion Diagnostics and Pharmacogenomics Market Report, Size, Share and Forecast 2026-2033: The Label Sets the Price, the Guideline Sets the Volume, which sizes the two fields separately rather than as one instrument category, and values the combined market at USD 6,820 million in 2025, reaching USD 12,957 million by 2033 at a compound annual rate of 8.35 per cent — an increment of USD 6,137 million, or 1.90 times the base year. The full report is available at https://www.pheonixresearch.com/healthcare/diagnostics/market-report/global-companion-diagnostics-and-pharmacogenomics-market/.

The report’s central finding is that these are not one market. They run on the same sequencers and the same real-time PCR instruments, frequently in the same laboratory, and they are priced by two authorities that do opposite things. A companion diagnostic is priced by a drug’s label, which makes the test non-substitutable and compulsory. A pharmacogenomic test is priced by a payer’s coverage policy, which can simply refuse to pay for it. Companion diagnostics compounds at 9.72 per cent; pharmacogenomics at 5.90 per cent. The 3.82-point gap is not a difference in science.

Field 2025 (USD m) 2033 (USD m) CAGR Share of 2025
Companion diagnostics 4,180 8,781 9.72% 61.29%
Pharmacogenomics 2,640 4,176 5.90% 38.71%
Total 6,820 12,957 8.35% 100.00%

Companion diagnostics supplies 74.97 per cent of the USD 6,137 million increment from a 61.29 per cent base — three quarters of the growth against three fifths of the starting level.

The payer will fund the guideline gene. It will not fund the panel.

The Clinical Pharmacogenetics Implementation Consortium maintains 28 active guidelines covering 34 genes and 164 drugs, with 85 per cent of published pharmacogenomic implementation studies referencing its content. It is the strongest evidence base in diagnostics, freely available, integrated into the Epic genomics module and queried through a public API more than 80,000 times a month.

It is also not a payment. The Medicare contractor that governs American coverage of pharmacogenomic testing set out its position in LCD L38294, effective 26 July 2020 and revised 2 October 2025. Gene-by-single-gene testing is covered consistent with CPIC. On combinatorial testing the contractor concluded there are “insufficient data to support coverage for any combinatorial test.”

That one sentence sets the shape of a USD 2,640 million field. Inside pharmacogenomics, single-gene and HLA testing compounds at 7.99 per cent and the multi-gene panel at 4.67 per cent — the reverse of the mix a vendor would choose, and the direct arithmetic of the coverage determination. Where a five-gene panel is refused, the same patient is often tested sequentially under covered single-gene codes. The clinical episode survives; the value migrates out of one panel and into several claims that each carry less.

The panel was USD 1,180 million against USD 890 million for single-gene testing in 2025. By 2033 it is USD 1,700 million against USD 1,646 million — a lead cut from USD 290 million to USD 54 million while the smaller line compounds at 1.71 times its rate.

A coverage decision is a revenue event with no offsetting lever

Myriad Genetics is the clean test case, because its 2025 results describe exactly what happens when a sales organisation meets a coverage wall. Full-year revenue of USD 824.5 million fell 2 per cent, of which USD 8.1 million was a fourth-quarter headwind from UnitedHealthcare discontinuing GeneSight coverage in commercial and managed Medicaid. GeneSight volume still grew 9 per cent in that quarter while absorbing the lost coverage.

A vendor cannot discount, bundle or out-compete its way back into a claim a contractor has decided not to pay. One payer’s coverage decision cost this field more than a year of clinical evidence added.

Every year more tests are run and each of them is worth less

Volume rises from 43.0 million tests to 96.0 million, a 10.56 per cent compound rate, against revenue growth of 8.35 per cent. The 221-basis-point gap means realised revenue per test falls from USD 158.60 to USD 134.97 — a 14.90 per cent decline across eight years.

That is not a defect in the construction. It is what happens when a test stops being a product and becomes a step in a pathway. And the companion diagnostics half carries the larger share of it, through a mechanism that will never appear as a single announcement: group labelling.

A comprehensive genomic profile cleared for one drug and later labelled for a group of oncology therapeutics stops being a test for a drug and becomes a test for a disease. Illumina’s TruSight Oncology Comprehensive holds separate companion indications for RET fusions in thyroid cancer and for RET SNVs, MNVs, insertions and deletions in medullary thyroid cancer under a single authorisation supplement; Thermo Fisher’s Oncomine Dx Express holds an ERBB2/HER2 activating-mutation indication in non-small-cell lung cancer. One platform, many labels, each of which adds patients without adding an instrument — and each of which converts a per-drug test into a per-patient test, so the per-drug premium disappears into the panel price. Every authorisation supplement is individually good news.

The field is also no longer defined by tissue. The FDA authorised a companion diagnostic for bepirovirsen in chronic hepatitis B by De Novo request in October 2026 — Elecsys HBsAg II quant II RxDx, reading hepatitis B surface antigen as the biomarker. Roche already reports companion diagnostics growing 25 per cent inside a Pathology Laboratory business growing 14 per cent.

Two revenue pools, and a number that gets counted twice

Companion diagnostics is usually sized as a single figure, and that is the second error the report corrects. The same clinical event generates revenue twice, and two different companies book it: a laboratory buys an assay kit from a manufacturer, then runs the test and bills a payer for it. The kit and the test are not two markets — they are two positions on one value chain applied to one patient.

Revenue pool 2025 (USD m) Share of market Who books it
Companion diagnostic assays, kits and reagents 2,460 36.07% IVD manufacturers
Companion diagnostic testing services 1,720 25.22% Reference and specialty laboratories
Pharmacogenomic assays and testing (combined) 2,640 38.71% Both, at a much smaller ticket
Total 6,820 100.00%

58.85 per cent of companion diagnostic revenue is the kit and 41.15 per cent is the test. A reader who treats the USD 4,180 million as the value of companion diagnostic testing overstates what payers spent on testing by more than half, and understates what manufacturers earned, because the two are different populations of company. This is a value-chain sum, not a measure of testing spend, and the report states the distinction on the page rather than in a footnote.

One pool is deliberately excluded. Pharmaceutical co-development fees, milestone payments and diagnostic-development service contracts are research and development spend by a drug sponsor, not diagnostic revenue. They are large and real, and including them would make this market incomparable with every other report in the cluster, because the same dollars already appear in pharmaceutical R&D budgets.

Concentrated at the assay layer, fragmented at the testing layer — and the concentration does not protect price

Twelve named participants account for USD 5,220 million of the USD 6,820 million market, 76.54 per cent, leaving a stated residual of USD 1,600 million, or 23.46 per cent. The top five hold USD 3,300 million, 48.39 per cent. That residual is materially lower than the 33-51 per cent band the other discipline reports in this cluster carry, and the reason is structural rather than better research: companion diagnostic revenue attributes cleanly because the label names the device, while pharmacogenomics is delivered by thousands of hospital laboratories running their own validated tests, and no accounts exist for them.

Roche is the largest position at USD 1,340 million — 19.65 per cent of the combined market and 32.06 per cent of the companion diagnostics field — and the only participant with a disclosed line in immunohistochemistry, real-time PCR and comprehensive genomic profiling at once. Its divisional R&D spend of CHF 2,052 million against CHF 13,847 million of diagnostics sales is 14.82 per cent of sales, roughly three times the intensity of a core laboratory franchise, and it is not directed at analytical chemistry. It is directed at evidence generation, trial by trial. In this market, research and development is not product development. It is the purchase of future labels.

The counter-intuitive part is that the concentration sits in the wrong place to hold a price. A manufacturer with an authorised device and a label behind it has no competitor for that indication — and no pricing power either, because the price was fixed in the launch negotiation and the payer is a monopsonist for the test the label requires. The margin has to come from menu instead: one platform holding many labels amortises a fixed development and authorisation cost across more indications. That is what group labelling enables, and it is why the platform owners are the structural winners even as revenue per test declines.

No participant is strong in both fields. Roche, Illumina, Thermo Fisher and Agilent hold companion diagnostic positions and no meaningful pharmacogenomic franchise; Myriad, Tempus and the reference laboratory networks hold pharmacogenomic volume and no authorisations of consequence. The two fields reward different organisations — a regulatory affairs and clinical-trial apparatus on one side, payer relations and health-system sales on the other. And the field is consolidating in one direction only: buyers are platform owners acquiring content, not diagnostic companies acquiring diagnostic companies. Roche’s position was assembled around Foundation Medicine rather than built assay by assay. What is being bought is the right to be on the label, accumulated across enough indications that the platform becomes the default.

North America is the only region where both price mechanisms run at full strength

North America is 43.99 per cent of the market in 2025, falling to 41.21 per cent — the only region where the MolDx coverage policy and the oncology label both operate at full force. Europe is the second pole at 26.98 per cent, and its structure differs: coverage is decentralised, so a panel refused by Medicare may be reimbursed by a German statutory insurer and refused by a French one.

The two fastest-growing regions are Latin America and the Middle East and Africa, which grow because they are building the testing layer rather than repricing it. Japan is the slowest: its fee schedule has already absorbed the pharmacogenomic revisions and its comprehensive profiling is reimbursed through a national pathway at a fixed price. A mature market with a shrinking population and no repricing event left does not compound.

One decision moves the terminal year by USD 1,643 million

The base case is USD 12,957 million in 2033. The downside, in which commercial payers follow UnitedHealthcare’s GeneSight withdrawal, covered single-gene testing is narrowed to a shorter CPIC list, and group labelling compresses per-test price faster than volume grows, is USD 11,300 million at 6.52 per cent. The upside, in which a national coverage determination reverses the L38294 combinatorial position and pan-tumour profiling is reimbursed at a single national rate, is USD 14,600 million at 9.98 per cent.

That band — 183 basis points below the base case and 163 above it — is wider than the other discipline reports in this cluster carry, and it is the correct shape for a market whose constraint is a coverage decision rather than a statutory fee. A national coverage determination is a binary event with a five-figure-million consequence in the terminal year. A fee schedule moves the same amount predictably, and in slices.

The report also holds its own first construction up for correction rather than smoothing it. An earlier mix assumed clinical utility evidence would eventually move the contractor. The contractor revised L38294 on 2 October 2025 and did not move. The base case now holds the payer’s stated position, the covered product takes the growth, and the panel-growing-at-the-single-gene rate case — worth USD 482 million of the USD 1,643 million upside — is carried as the upside rather than folded into the base.

Scope

This report counts companion diagnostic assays, kits, reagents and testing services, and pharmacogenomic genotyping, panels, testing services and interpretation software and clinical decision support, delivered to reference and specialty laboratories, hospital and health-system laboratories, pharma-sponsored trial testing, academic medical centres and payer and population pharmacogenomic programmes. It excludes pharmaceutical co-development fees and milestone payments, general molecular diagnostics revenue already counted inside the discipline reports of this cluster, and instrument placement revenue for platforms already counted elsewhere.

Method

Seventy per cent secondary, thirty per cent primary. The secondary layer is the disclosure set read directly rather than summarised: FDA companion diagnostic authorisations, CMS coverage determinations including LCD L38294, CPIC guideline publications, audited company results and statutory instruments. The primary layer is 52 depth interviews across 11 markets, 31 open-ended interviews conducted around coverage and label cycles in the United States, Germany, Japan and the Gulf Cooperation Council, a 198-respondent structured survey of laboratory and pharmacy leaders, and structured observation at four conferences. The primary layer is used for mechanism only: every market level, share, growth rate and forecast derives from the secondary layer or from arithmetic performed on it, and no interview or survey response carries a figure. All CAGRs, shares and revenue-per-test figures were computed deterministically and are reproducible from the tables in the report. Currency conversions use EUR 1.13/USD, CHF 1.15/USD and JPY 148/USD throughout, the same basis as every other report in this cluster. No market-research competitor material was cited, quoted or used to set any level.

About this report

Global Companion Diagnostics and Pharmacogenomics Market Report, Size, Share and Forecast 2026-2033: The Label Sets the Price, the Guideline Sets the Volume is available at https://www.pheonixresearch.com/healthcare/diagnostics/market-report/global-companion-diagnostics-and-pharmacogenomics-market/, with competitive landscape, value chain and revenue model, investment activity, technology and innovation, market risk and regulatory landscape chapters, plus regional, product, end-market and sensitivity analysis, and the full methodology and scope definitions summarised above.

About Pheonix Research

Pheonix Research is a market intelligence platform that sizes markets bottom-up from physical volume and prices them at the point where a buyer actually pays, then translates the result into role-specific decisions. Its research is organised around value chains rather than industry labels: the same market looks different to procurement, to strategy and to the executive, and the output is built to end in an action and a timeframe rather than a chart. Pheonix publishes market reports, bespoke intelligence engagements, the role-based VALUE platform and curated signal bundles. For further information, visit https://www.pheonixresearch.com/.